anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a Phase 4, single-center, randomized clinical trial of the immune responses of children given one of two licensed influenza vaccines (either inactivated vaccine given IM or live, attenuated vaccine given intranasally). This study will enroll 40 healthy children 5-9 years of age. Subjects will be randomized to receive either FluMist or Fluzone. FluMist is approved for children older than 5 years and Fluzone is also approved for a broader age indication starting at 6 months of age. Subjects who receive FluMist will have the vaccine administered intranasally by large particle aerosol, 0.25 mL per nostril. Subjects receiving Fluzone will receive 0.5 mL given intramuscularly into the non-dominant deltoid muscle. Children who have not previously been immunized against influenza will receive a second dose of vaccine 4 weeks after the first dose. Children who receive two doses of vaccine will remain on the study for 8-10 weeks. The primary objective of this study is to compare the effector B cell responses at Day7-9 and the CD4 and CD8 T-cell responses, memory B-cell and the serology responses at Day 28 post-immunization following administration of one of two different influenza vaccines. Researchers will evaluate any increases in the immune response (CD4, CD8, B cell and serology responses) Day 0 to Day 7-9 for T-cells and ASCs, and from Day 0-28 for memory B-cell and serology responses. NK-cell and homing studies will also be compared between the groups.
FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention relates to substituted derivatives of benzo(b)thiepine-1,1-oxides and their additive salts with acids of the formula (I)   wherein R 1  is methyl, ethyl, propyl, butyl; R 2  is hydrogen atom, hydroxyl; R 3  is a residue of amino acid, diamino acid being residue of amino acid, residue of diamino acid are mono- or multiple substituted, if necessary, with amino-protective group; R 4  is methyl, ethyl, propyl, butyl; R 5  is methyl, ethyl, propyl, butyl; Z is covalent bond. Invention describes also method for preparing compounds, medicine based on thereof and method for preparing medicine. Compounds can be used as hypolipidemic agents. EFFECT: improved preparing method, valuable medicinal properties of compounds. 6 cl, 1 tbl, 4 ex
The anticipated 2000 old CAD patients aged≥65years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
Background: The optimal ampicillin-sulbactam dosing regimen for carbapenem-susceptible Acinetobacter baumannii isolates in critically ill trauma patients has not been clearly defined. One strategy to provide the adequate sulbactam dose includes high-dose continuous infusion. Case(s) Description: We present three cases of critically ill trauma patients with augmented renal clearance treated with high-dose ampicillin-sulbactam through an intravenous continuous infusion for ventilator-associated pneumonia. All A. baumannii isolates were susceptible to sulbactam with low minimum inhibitory concentrations. All achieved clinical cure at the end of therapy and no recurrent pneumonia was noted. No clinically substantial adverse effect attributable to ampicillin-sulbactam therapy occurred. Discussion: There is limited evidence to endorse high-dose, continuous infusion ampicillin-sulbactam for treatment of infections caused by carbapenem-susceptible A. baumannii. This report presents three critically ill trauma patients with augmented renal clearance that achieved positive clinical outcomes with higher doses of ampicillin-sulbactam administered through a continuous infusion.
OBJECTIVES: Based on enhanced MRI, a prediction model of microvascular invasion (MVI) for hepatocellular carcinoma (HCC) was developed using graph convolutional network (GCN) combined nomogram.
METHODS: We retrospectively collected 182 HCC patients confirmed histopathologically, all of them performed enhanced MRI before surgery. The patients were randomly divided into training and validation groups. Radiomics features were extracted from the arterial phase (AP), portal venous phase (PVP), and delayed phase (DP), respectively. After removing redundant features, the graph structure by constructing the distance matrix with the feature matrix was built. Screening the superior phases and acquired GCN Score (GS). Finally, combining clinical, radiological and GS established the predicting nomogram.
RESULTS: 27.5% (50/182) patients were with MVI positive. In radiological analysis, intratumoural artery (P = 0.007) was an independent predictor of MVI. GCN model with grey-level cooccurrence matrix-grey-level run length matrix features exhibited area under the curves of the training group was 0.532, 0.690, and 0.885 and the validation group was 0.583, 0.580, and 0.854 for AP, PVP, and DP, respectively. DP was selected to develop final model and got GS. Combining GS with diameter, corona enhancement, mosaic architecture, and intratumoural artery constructed a nomogram which showed a C-index of 0.884 (95% CI: 0.829-0.927).
CONCLUSIONS: The GCN model based on DP has a high predictive ability. A nomogram combining GS, clinical and radiological characteristics can be a simple and effective guiding tool for selecting HCC treatment options.
ADVANCES IN KNOWLEDGE: GCN based on MRI could predict MVI on HCC.
BACKGROUND AND AIMS: The International AIH Pathology Group (IAIH-PG) put forward the new histological criteria of autoimmune hepatitis (AIH) in 2022, which have not undergone adequate verification. In this study, we verified the applicability of the new histological criteria in the population of Chinese patients with chronic liver disease, comparing it with the simplified criteria.
METHODS: The gold standard for diagnosis in all patients was based on histological findings, combined with clinical manifestations and laboratory tests and determined after a follow-up period of at least 3 years. A total of 640 patients with various chronic liver diseases from multiple centres underwent scoring using the new histological criteria and the simplified criteria, comparing their diagnostic performance.
RESULTS: In this study, the new histological criteria showed a sensitivity of 73.6% and 100% for likely and possible AIH, with specificities of 100% and 69.0% respectively. The coincidence rates of possible AIH for the new histological criteria, simplified histological criteria and simplified score were 81.7%, 72.8% and 69.7% respectively. For likely AIH, the rates were 89.2%, 75.9% and 65.6% respectively. Based on the new histological criteria, all patients with AIH were correctly diagnosed. Specifically, 73.6% were diagnosed with likely AIH and 26.4% were possible AIH. Additionally, the simplified histological criteria achieved a diagnosis rate of 98.6% for AIH, while the simplified score could only diagnose 53.8% of AIH.
CONCLUSIONS: Compared with the simplified score and simplified histological criteria, the sensitivity and specificity of the new histological criteria for AIH were significantly improved. The results indicate that the new histological criteria exhibit high sensitivity and specificity for diagnosing AIH in China.
Patients in the PDT group were treated in a single session on the day of admission to the clinic. Indocyanine green (Perio green, Elexxion AG, Radolfzell, Germany) prepared and applied according to manufacturer's instructions steps (mixing, application, soaking phase, rinsing, activation) in a concentration with 0.1mg/mL was administered via fine-needle syringe as the photosensitizer. Following the completion of topical application of the photosensitizer to the lesion surface, a (GaAlAs) diode laser device (Cheese Diode Laser, Wuhan Gigaa Optronics Technology Co. Ltd, China) in continuous mode (810 nm, 300 mW, 10,000 kHz, 1.26 cm2 spot area), with a 400 μm polymethylmethacrylate optical fiber tip, scanning from the periphery to the center of the lesion with an energy density of approximately 10 J/cm2 for 40 s and applied non-contact at a distance of 1 mm.
In the ESPB group, after the patients are placed in the prone position, the linear ultrasound probe will be placed in the midline in the transverse plane to visualize the spinous processes, and the transverse process, trapezius, latissimus dorsi and erector spina muscles will be visualized on the side where VATS is planned at the T5 vertebra level. With an 'in-plane' approach, using a 22 gauge 5-8 cm block needle with extension line (Braun, Melsungen, Germany), which can be seen on ultrasound, the skin, subcutaneous and trapezius, latissimus dorsi and erector spina muscles are passed in the cranio-caudal direction and 0.5- After confirming the needle site with 1 ml of saline, the ESPB will be administered with 20 ml of 0.5% bupivacaine by visualizing the local anesthetic spread linearly.
A process for preparing a cortin-like product is characterized in that the milk or mamma and teat from a mammal, particularly the cow, is extracted at lower than room temperature, preferably between - 5 DEG  C. and + 2 DEG  C., by a solvent of steroids which is miscible with water, and the extract is purified.  Specified solvents are acetone, ethyl acetate, chloroform, methyl alcohol, ethyl alcohol and mixtures of ethyl alcohol and acetone, and ethyl acetate and chloroform.  The extraction is preferably effected after acidification to a pH of 4.5-5 with mineral or organic acid, such as hydrochloric acid or acetic acid, and after agitation of starting material with solvent the mixture is preferably left at lower than room temperature before separating the extract.  The residue of the extraction may be hydrolysed in an aqueous acid medium and the aqueous hydrolysis product further extracted, the extract obtained being added to the main extract. Purification of the extract is effected by means of successive evaporations and extractions, each evaporation being preceded by filtration and the successive evaporations and extractions are continued until an insoluble residue is no longer obtained.  An example describes the preparation of an extract from whole milk in the form of an aqueous solution containing 15% ethyl alcohol which is suitable for administration orally or by injection.
The invention discloses application of tablets for treating the osteomyelitis to preparation of a medicament for treating the anemopyretic cold. The tablets for treating the osteomyelitis have a prescription of honeysuckle flower, dandelion, violet herb, barbed skullcap herb, Chinese pulsatilla root and hedyotis diffusa, are sugar coated tablets, show brownish black after sugar coats are removed, have slightly bitter taste, have moisture absorbance property, can be used for dissipating blood stasis and swell, are used in heat and blood stasis patients suffering from suppurative osteomyelitis and osteomyelitis and have specification of weight of 0.4 gram per tablet. Each tablet is equivalent to 3 grams of raw medicinal materials. The tablets for treating the osteomyelitis are taken orally. 8 to 10 tablets are taken each time. The tablets are taken for three times each day. Current, the effect that the tablets can be used for treating the anemopyretic cold is found.
The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. The disclosure describes isolated peptides comprising at least 70% sequence identity to a peptide of one of SEQ ID NOS:1-107. The peptide may comprise at least 6 contiguous amino acids of a peptide of one of SEQ ID NOS:1-107. The disclosure also describes a peptide comprising at least 6 contiguous amino acids from a peptide of one of SEQ ID NOS:1-107, wherein the peptide comprises an alternative splice site junction. Also described is a polypeptide comprising the peptide, pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. The nucleic acids of the disclosure include nucleic acids that are RNA or DNA. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.
Known patients colonized rectally with ESBL-producing enterobacteriaceae and subjected to antibiotic pressure (antibiotic therapy predicted greater than 24 hours) with beta-lactams or dual therapy comprising a beta-lactam. The prescription of antibiotic therapy, a decision independent of the study procedures, will be carried out as part of routine care in the context of microbiologically documented infection. The choice of molecules will be left to the discretion of clinicians.
The invention provides a lignum Aquilariae Resinatum [ 2 ] with the activities of promoting collagen secretion and resisting oxidation Aquilariasinensis (Lour.)Spreng.]Flower plant extract, and its preparation method and application are provided. Belongs to the technical field of cosmetics and medicines. The extract is prepared by extracting dried aquilaria sinensis flower (Inula sikkmensis hook) with distilled water to obtain PXS64, and sequentially eluting PXS64 with macroporous resin water and 30% ethanol to obtain a pure water part PXS64-1 and a 30% ethanol elution part PXS64-2. Experimental researches on in vitro collagen secretion promotion and DPPH removal experiments show that the aquilaria sinensis flower extract, namely the aquilaria sinensis flower extract PXS64, PXS64-1 and PXS64-2, has the activity of promoting collagen secretion; meanwhile, the aquilaria sinensis flower extract PXS64 has DPPH free radical scavenging activity. The aquilaria sinensis extract PXS64, PXS64-1, PXS64-2 provide a new choice for the application of the aquilaria sinensis extract PXS64, PXS64-1, PXS64-2 in preparing anti-oxidation and anti-aging medicines or skin care products.
The invention provides siRNA for specifically inhibiting the expression of a miR-130b gene. A sequence of the miR-130b gene is shown in SEQ ID NO: 1, and a sequence of the siRNA is shown in SEQ ID NO: 2. The invention also provides an expression vector specifically for the miR-130b gene, wherein the vector contains the siRNA shown in the sequence. The siRNA or/and the expression vector can be applied to the preparation of a medicament for improving the treatment effect of liver cancer. In the medicament, a medicament which performs targeted inhibition on the miR-130b gene is taken as an effective ingredient. The self-renewal capacity of liver cancer stem cells (CSC) is blocked through the siRNA for specifically inhibiting the expression of the miR-130b gene and the expression vector on which a miR-130b antisense strand nucleotide is loaded as well as the function that the siRNA and the expression vector are specifically combined with miR-130b to block the miR-130b, so that the sensitivity of the liver CSC to chemotherapy medicaments is improved.
Proteinaceous substances in these solutions are fractionally precipitated with polyethylene glycol (pref. mol. wt. 1000-2000) solutions (preferred concentration 50%) at a pH between 7 and 9 (pref. 8.5) at an optimum temp. of 4-5 degrees C. From the main fraction the virus is recovered in the crystalline form without undesirable proteinaceous contaminations, which may evoke allergic reactions.
JEUVEAU is supplied in a single-dose 100 Unit vial. Prior to intramuscular injection, reconstitute each vacuum-dried vial of JEUVEAU with only sterile, preservative-free 0.9% Sodium Chloride Injection, USP to obtain a reconstituted solution at a concentration of 4 Units/0.1 mL and a total treatment dose of 20 Units in 0.5 mL (see Table 1). Slowly inject the diluent into the vial. Discard the vial if a vacuum does not pull the diluent into the vial. Dispose of any unused saline. Gently mix JEUVEAU with 0.9% Sodium Chloride Injection USP by rotating the vial. JEUVEAU should be administered within 24 hours after reconstitution. During this time period, unused reconstituted JEUVEAU should be stored in a refrigerator between 2° to 8°C (36°F to 46°F) in the original carton to protect from light for up to 24 hours until time of use. Do not freeze reconstituted JEUVEAU. JEUVEAU vials are for single-dose only. After reconstitution, JEUVEAU should be used for only one injection session and for only one patient. Discard any remaining solution after administration.

Reconstituted JEUVEAU should be clear, colorless, and free of particulate matter otherwise it should not be injected. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
BACKGROUND AND AIMS: Subcutaneous adipose tissue (SAT) dysfunction contributes to NAFLD pathogenesis and may be influenced by the gut microbiota. Whether transcript profiles of SAT are associated with liver fibrosis and are influenced by synbiotic treatment (that changes the gut microbiome) is unknown. We investigated: (a) whether the presence of clinically significant, ≥F2 liver fibrosis associated with adipose tissue (AT) dysfunction, differential gene expression in SAT, and/or a marker of tissue fibrosis (Composite collagen gene expression (CCGE)); and (b) whether synbiotic treatment modified markers of AT dysfunction and the SAT transcriptome.
METHODS: Sixty-two patients with NAFLD (60 % men) were studied before and after 12 months of treatment with synbiotic or placebo and provided SAT samples. Vibration-controlled transient elastography (VCTE)-validated thresholds were used to assess liver fibrosis. RNA-sequencing and histological analysis of SAT were performed to determine differential gene expression, CCGE and the presence of collagen fibres. Regression modelling and receiver operator characteristic curve analysis were used to test associations with, and risk prediction for, ≥F2 liver fibrosis.
RESULTS: Patients with ≥F2 liver fibrosis (n = 24) had altered markers of AT dysfunction and a SAT gene expression signature characterised by enrichment of inflammatory and extracellular matrix-associated genes, compared to those with <F2 fibrosis (n = 38). Differences in transcript profiles between patients with vs without ≥F2 liver fibrosis were largely explained by adjusting for differences in HOMA-IR. Gut microbiome-modifying synbiotic treatment did not change SAT transcriptomic profiles or circulating inflammatory/adipokine markers. SAT CCGE values were independently associated with (8.38 (1.72-40.88), p = 0.009), and were a good predictor of, ≥F2 fibrosis (AUROC 0.79, 95 % CI 0.69-0.90). Associations between SAT transcriptomic profiles and ≥F2 fibrosis were reproduced using end-of-trial data.
CONCLUSION: A differential gene expression signature in SAT associates with ≥F2 liver fibrosis is explained by a measure of systemic insulin resistance and is not changed by synbiotic treatment. SAT CCGE values are a good predictor of ≥F2 liver fibrosis in NAFLD.
Purple urine bag syndrome (PUBS) is a rare and unusual event. It is related to symptomatic urinary infection and asymptomatic bacteriuria in patients with indwelling bladder catheters. The purple color of the urine is due to metabolic products of biochemical reactions formed by bacterial enzymes in the urine. Gastrointestinal tract flora breaks down the amino acid tryptophan into indole, which is subsequently absorbed into the portal circulation and converted into indoxyl sulfate. Indoxyl sulfate is then excreted into the urine, where it can be broken down into indoxyl if the appropriate alkaline environment and bacterial enzymes are present. The breakdown products, indigo, and indirubin appear blue and red. We reported on an elderly woman who was kept in a nursing home, had multiple comorbidities such as history of cerebrovascular accident (CVA), acute kidney injury (AKI) and she was hospitalized due to decreased consciousness, fever and kidney failure. On the third day of hospitalization, the patient developed PUBS while undergoing urinary catheterization in the hospital. She had no history of previous catheterization and chronic use of antibiotics, she was only using Tolterodine for a long time due to urinary urgency. Due to antibiotic resistance, the drugs were not changed and the purple color disappeared after changing the catheter and urinary bag.This was the first patient in this region to be reported with this manifestation.
IL-4R was injected subcutaneously. Base line and treatment end point nasal polyp score were compared and NPS \>1.
The invention relates to a metoprolol fumarate film-controlled slow-release pellet capsule. A slow-release film of the metoprolol fumarate film-controlled slow-release pellet utilizes Eurdragit RS 30D as a film-formation material. A pellet core of the metoprolol fumarate film-controlled slow-release pellet contains croscarmellose sodium having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 5 to 20wt% of croscarmellose sodium. The slow-release film comprises Eurdragit RS 30D, triethyl citrate as a plasticizer, and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RS 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 18 to 33%. The metoprolol fumarate film-controlled slow-release pellet comprises the pellet core containing croscarmellose sodium having high water expansibility and thus after absorbing water, the metoprolol fumarate film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the metoprolol fumarate film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.
A system for evaluating the reliability of an early warning score (EWS) is provided. The system receives patient test data and determines an EWS for the patient. A real-time feature extractor extracts features from the patient test data. A reliability score evaluator generates a reliability score for the EWS by processing the extracted features through a reliability score regression model. An inference engine generates inferences based on the reliability score and the extracted features. The inferences can be displayed on a user interface. The reliability score regression model can be determined via deep learning training. The training portion of the system receives training data sets. A data annotator assigns each training data set a reliability annotation. A training feature extractor generates extracted training features from the training data sets. A deep learning trainer uses the extracted training features and the reliability annotations to generate the reliability score regression model.